Intervention Review

You have free access to this content

Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection

  1. Juan Carlos Villar1,*,
  2. Juan Guillermo Perez2,
  3. Olga Lucia Cortes2,
  4. Adelina Riarte3,
  5. Micah Pepper4,
  6. Jose Antonio Marin-Neto5,
  7. Gordon H Guyatt6

Editorial Group: Cochrane Heart Group

Published Online: 27 MAY 2014

Assessed as up-to-date: 10 FEB 2014

DOI: 10.1002/14651858.CD003463.pub2


How to Cite

Villar JC, Perez JG, Cortes OL, Riarte A, Pepper M, Marin-Neto JA, Guyatt GH. Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection. Cochrane Database of Systematic Reviews 2014, Issue 5. Art. No.: CD003463. DOI: 10.1002/14651858.CD003463.pub2.

Author Information

  1. 1

    Universidad Autónoma de Bucaramanga (Colombia), Department of Medicine, Bucaramanga, Santander, Colombia

  2. 2

    Fundación Cardioinfantil Instituto de Cardiología, Bogota, Colombia

  3. 3

    Instituto Nacional de Parasitología Dr M Fatala Chaben, Departamento de Clínica, Patología y Tratamiento, Buenos Aires, Buenos Aires, Argentina

  4. 4

    Boston University, School of Public Health, Boston, USA

  5. 5

    University of Sao Paulo, Medical School of Ribeirao Preto, Ribeirao Preto, Sao Paulo, Brazil

  6. 6

    McMaster University, Department of Clinical Epidemiology and Biostatistics, Hamilton, Ontario, Canada

*Juan Carlos Villar, Department of Medicine, Universidad Autónoma de Bucaramanga (Colombia), Grupo de Cardiología Preventiva, UNAB Campus el Bosque Calle 157 No. 19-55, Bucaramanga, Santander, Colombia. jvillar@unab.edu.co.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 27 MAY 2014

SEARCH

[Figure 1]
Figure 1. Quality assessment of the studies other than RCTs included.
[Figure 2]
Figure 2. Study flow diagram.
[Figure 3]
Figure 3. Main characteristics of the included studies.
[Figure 4]
Figure 4. Quality assessment of randomised controlled trials included.
[Figure 5]
Figure 5. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

*Non-randomised experiment

**Observational study
[Figure 6]
Figure 6. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 7]
Figure 7. Meta-regression analysis. Relationship between effect of TT on progression of CCC and serology.
[Figure 8]
Figure 8. Meta-regression analysis. Relationship between effect of TT on mortality and serology.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Parasite-related outcomes, Outcome 1 Positive serology.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Parasite-related outcomes, Outcome 2 Positive PCR: nitroderivatives.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Parasite-related outcomes, Outcome 3 Positive xenodiagnosis: all populations, all tested drugs.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Parasite-related outcomes, Outcome 4 Mean reduction of antibodies titres: all populations, all tested drugs.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Patient-related outcomes: efficacy, Outcome 1 ECG abnormalities - RCT data - benznidazole.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Patient-related outcomes: efficacy, Outcome 2 Progression of cardiomyopathy: non-RCT data - adults, nitroderivatives.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Patient-related outcomes: efficacy, Outcome 3 Mortality: non-RCT data - adults, all tested drugs.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Patient-related outcomes: safety, Outcome 1 BZD mild-to-moderate - RCT data only.
[Analysis 3.3]
Analysis 3.3. Comparison 3 Patient-related outcomes: safety, Outcome 3 BZD severe side effects.
[Analysis 3.5]
Analysis 3.5. Comparison 3 Patient-related outcomes: safety, Outcome 5 ALLOP - mild-to-moderate - RCT data only.
[Analysis 3.6]
Analysis 3.6. Comparison 3 Patient-related outcomes: safety, Outcome 6 ALLOP - severe side effects.
[Analysis 3.7]
Analysis 3.7. Comparison 3 Patient-related outcomes: safety, Outcome 7 NFTMX - severe side effects.
[Analysis 3.8]
Analysis 3.8. Comparison 3 Patient-related outcomes: safety, Outcome 8 ITRA - severe side effects.
[Analysis 3.9]
Analysis 3.9. Comparison 3 Patient-related outcomes: safety, Outcome 9 Drug discontinuation - all populations, all drugs.